Neurome’s technology platform has been developed to permit discovery of innovative therapeutic solutions to a variety of disease susceptibilities relevant to human health. This technology platform is comprised of:

Discovery Technologies, which include the patented gene expression profiling technology, TOGA®, enabling the discovery and evaluation of new molecular targets for intervention strategies;

Screening Technologies, providing a competitive edge in the identification and characterization of the cells that express these molecular targets; and

Vaccine Technologies, focusing on targeted, receptor-mediated delivery of mucosal vaccines.

Neurome’s technology platform is especially well suited to the comprehensive preclinical evaluation of drug candidates that may be useful in addressing defects associated with the cell classes and circuits that are at the core of human neurologic disorders.